Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥31m2024-01-01 → 2024-06-30StandaloneNet sales
Revenue¥63m2023-01-01 → 2023-12-31StandaloneNet sales (5-year summary)
Revenue¥63m2023-01-01 → 2023-06-30StandaloneNet sales
Operating income−¥793m2024-01-01 → 2024-06-30StandaloneOperating income
Operating income−¥901m2023-01-01 → 2023-06-30StandaloneOperating income
Ordinary income−¥753m2024-01-01 → 2024-06-30StandaloneOrdinary income
Ordinary income−¥1.9bn2023-01-01 → 2023-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥867m2023-01-01 → 2023-06-30StandaloneOrdinary income
Profit before tax−¥753m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax−¥867m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥755m2024-01-01 → 2024-06-30StandaloneProfit loss
Net income−¥1.9bn2023-01-01 → 2023-12-31StandaloneNet income loss (5-year summary)
Net income−¥869m2023-01-01 → 2023-06-30StandaloneProfit loss
Total assets¥1.9bnat 2024-06-30StandaloneAssets
Total assets¥2.0bnat 2023-12-31StandaloneAssets
Total assets¥1.9bnat 2023-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥469mat 2024-06-30StandaloneLiabilities
Total liabilities¥567mat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.4bnat 2024-06-30StandaloneNet assets
Net assets / equity¥1.5bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.3bnat 2023-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.1bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥1.5bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥872mat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2022-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥1.1bn2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥452m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥1m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥5m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥748,0002023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥686m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥45m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-36.962024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-108.922023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-50.162023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio74.7%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.5%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio68.7%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued20,961,600at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued19,717,100at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2023-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 438
ItemContextValueUnit
Proceeds from long term loans payable fin cfCurrentYTDDuration_NonConsolidatedMember100000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration_NonConsolidatedMember-52774000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration_NonConsolidatedMember-44440000JPY
Repayments of lease obligations fin cfPrior1YTDDuration_NonConsolidatedMember-1780000JPY
Repayments of lease obligations fin cfCurrentYTDDuration_NonConsolidatedMember-4929000JPY
Proceeds from issuance of common stock fin cfPrior1YTDDuration_NonConsolidatedMember-JPY
Proceeds from issuance of common stock fin cfCurrentYTDDuration_NonConsolidatedMember638294000JPY
Payments for issuance of common stock fin cfPrior1YTDDuration_NonConsolidatedMember-JPY
Payments for issuance of common stock fin cfCurrentYTDDuration_NonConsolidatedMember-2466000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration_NonConsolidatedMember45445000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration_NonConsolidatedMember686458000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration_NonConsolidatedMember30994000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember23573000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration_NonConsolidatedMember-375860000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration_NonConsolidatedMember-415305000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember1466201000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1287763000JPY
Cash and cash equivalentsPrior1QuarterInstant_NonConsolidatedMember1090340000JPY
Cash and cash equivalentsCurrentQuarterInstant_NonConsolidatedMember872457000JPY
Directors compensations sgaPrior1YTDDuration_NonConsolidatedMember48486000JPY
Directors compensations sgaCurrentYTDDuration_NonConsolidatedMember51291000JPY
Salaries and allowances sgaPrior1YTDDuration_NonConsolidatedMember93792000JPY
Salaries and allowances sgaCurrentYTDDuration_NonConsolidatedMember100704000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember636952000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember523975000JPY
Business consignment expenses sgaPrior1YTDDuration_NonConsolidatedMember45350000JPY
Business consignment expenses sgaCurrentYTDDuration_NonConsolidatedMember48079000JPY
License fee sgaPrior1YTDDuration_NonConsolidatedMember16679000JPY
License fee sgaCurrentYTDDuration_NonConsolidatedMember12616000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-08-09
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第21期中(自 2024年1月1日 至 2024年6月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長 浦田 泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目1番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03-5472-1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)経理・財務部長  米尾 哲治
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目1番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-5472-1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経理・財務部長  米尾 哲治
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant-
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant-

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2023-12-31pass rounding
balance sheet identitynon_consolidated 2024-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass